We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Macrophages Form Vascular Mimicry Channels to Supply Growing Tumors

By Gerald M. Slutzky, PhD
Posted on 22 Nov 2016
A potential new therapeutic approach to block cancer development is based on the finding that macrophages form primitive non-endothelial “vessels” or vascular mimicry channels that help supply growing tumors with oxygen and nutrients.

Vascular mimicry has been observed in several types of solid tumors, including glioblastoma, breast cancer, and melanoma, and has been attributed to a sub-population of cells within the tumor called cancer stem cells. More...
Macrophages, key cells of the innate immune system, are known to support vascular development but were not believed to directly form vessel walls. New evidence has changed this concept, as investigators at the Scripps Research Institute (La Jolla, CA, USA) reported in November 11, 2016, online edition of the journal Scientific Reports that they had found that macrophages structurally formed primitive vascular mimicry (VM) channels in both tumor and angiogenesis in vivo models. These channels, which were lined with cells that expressed macrophage cell surface markers, were functionally connected to the systemic vasculature, as they were perfused by intravenously injected dye.

Since both models shared hypoxic micro-environments, the investigators hypothesized that hypoxia may be an important mediator of VM formation. Indeed, results showed that conditional genetic depletion of myeloid-specific HIF-1alpha (hypoxia inducible factor-1 alpha) resulted in decreased VM network formation, dye perfusion, and tumor size. The VM channels appeared to be too small to transport red blood cells, but the researchers suggested that the low oxygen concentrations within tumors drove macrophages to form this network of channels to transport dissolved oxygen and glucose.

"This may represent a whole new therapeutic target for treating tumors,” said senior author Dr. Martin Friedlander, a research professor at the Scripps Research Institute.

Related Links:
Scripps Research Institute


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.